Invents & Invests

in biotechnology companies that aim to drastically improve medicine

Learn How

About Us

Boxer Capital, LLC, is a private biotechnology investment fund based in San Diego, California that invents and invests in drug development across multiple therapeutic indications.

Founded by the life sciences team at Tavistock Group in 2005, we maintain a concentrated portfolio of public and private companies.

Our Values

Integrity

We are committed to upholding the highest standards in honesty, loyalty, and accountability to ourselves and others.

Commitment

We are passionate, creative, and disciplined in generating exceptional results.

Stewardship

We treat people with kindness and respect as we maintain a culture of excellence.

Investment Philosophy & Process

Through disciplined analysis, we identify investment opportunities focused on transformative medical advancements throughout the business life-cycle - from positions with mature biotechnology companies, to helping build new biotechnology companies from the ground up.

Our expert team includes scientists and clinicians who have led research and discovery across multiple therapeutic indications. Several members of our team continue to practice medicine and have had the privilege of leading clinical development for multiple drugs that are treating patients today. This unique combination of medical expertise and investment expertise has led to a 14-year proven track record, positioning Boxer as a key player within the biotechnology and life science investment industry.

Life-Changing Medical Advancements

We invent and invest in biotechnology companies that aim drastically improve medicine, particularly for severe medical illnesses, including oncology and rare disease.

Multi-Pronged
Analysis

Our team of medical and investment experts conduct extensive due diligence on every deal, including scientific, clinical, and quantitative analysis.

Translating Innovation into Opportunity

By marrying the fundamentals of a company with "big picture" thinking of the industry and sub-sectors, we translate inefficiencies in the biotechnology industry into investment opportunities.